Genomic predictors of treatment response in prostate cancer
Update: 2017-07-31
Description
Dr Bristow speaks with ecancer at WIN 2017 about trials ongoing with patients in the Canadian Prostate Cancer Genome Network (CPC-GENE) to determine patient subgroups most at risk of disease progression and drug resistance.
He notes the use of imaging to guide treatment and gauge response, and considers the significance of the abiraterone data from earlier this year at ASCO 2017.
He notes the use of imaging to guide treatment and gauge response, and considers the significance of the abiraterone data from earlier this year at ASCO 2017.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
